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Abstract
Introduction: Disclosure of HIV status to children is essential for disease management but is not well characterized in
resource-limited settings. This study aimed to describe the prevalence of disclosure and associated factors among a cohort
of HIV-infected children and adolescents in Kenya.
Methods: We conducted a cross-sectional study, randomly sampling HIV-infected children ages 6–14 years attending 4 HIV
clinics in western Kenya. Data were collected from questionnaires administered by clinicians to children and their caregivers,
supplemented with chart review. Descriptive statistics and disclosure prevalence were calculated. Univariate analyses and
multivariate logistic regression were performed to assess the association between disclosure and key child-level
demographic, clinical and psychosocial characteristics.
Results: Among 792 caregiver-child dyads, mean age of the children was 9.7 years (SD= 2.6) and 51% were female.
Prevalence of disclosure was 26% and varied significantly by age; while 62% of 14-year-olds knew their status, only 42% of
11-year-olds and 21% of 8-year-olds knew. In multivariate regression, older age (OR 1.49, 95%CI 1.35–1.63), taking
antiretroviral drugs (OR 2.27, 95%CI 1.29–3.97), and caregiver-reported depression symptoms (OR 2.63, 95%CI 1.12–6.20)
were significantly associated with knowing one’s status. Treatment site was associated with disclosure for children
attending one of the rural clinics compared to the urban clinic (OR 3.44, 95%CI 1.75–6.76).
Conclusions: Few HIV-infected children in Kenya know their HIV status. The likelihood of disclosure is associated with
clinical and psychosocial factors. More data are needed on the process of disclosure and its impact on children.
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Introduction
In 2011, the World Health Organization (WHO) estimated
there were 3.4 million children under 15 years of age living with
the Human Immunodeficiency Virus (HIV), while an estimated
330,000 children were newly infected in 2011 alone. [1] The
advent of antiretroviral therapy (ART) and expanded access to
treatment have resulted in more HIV-infected children reaching
adolescence and adulthood, [2] especially in resource-limited
settings like sub-Saharan Africa, which is home to over 90% of the
pediatric HIV-infected population. [1] As HIV-infected children
live longer, emerging challenges to comprehensive pediatric HIV
care include supporting high rates of adherence to treatment,
preventing secondary transmission and promoting overall physical
and mental health. [3] For these children, learning about their
HIV diagnosis - often referred to as disclosure - is an important
step towards long-term disease management and necessary for the
transition from pediatric care into adolescent and adult care
settings. [4].
In the United States, recommendations for disclosure of HIV
status to children endorse a gradual process of giving age-
appropriate information as the child develops the cognitive and
emotional maturity to process this information. [5] Globally,
institutions such as the WHO have issued similar guidelines, [6]
but there are few published data on standardized, culturally
appropriate disclosure protocols in resource-limited settings. A
recent review on disclosure of HIV status to children found that
lower proportions of children in low- and middle-income countries
(LMIC) knew their status compared to those in high-income
countries and among those that did know, children in LMIC
reported learning it at older ages. [7] Of the 21 studies included for
review by Pinzon-Iregui et al. that reported prevalence of
disclosure, median prevalence of disclosure among similarly aged
children was 20% in studies conducted in LMIC and 43% in high-
income countries, while median age of disclosure was 9.6 years in
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Figure 1. Disclosure questionnaire items.
doi:10.1371/journal.pone.0086616.g001
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LMIC and 8.3 years in high-income countries. Caregivers in both
resource-poor and resource-rich settings report weighing the
potential risks and benefits of disclosure. While the child’s
increasing age, independence and concerns about medication
adherence may motivate caregivers to disclose, caregivers often
have fears about the negative emotional effects of disclosure and
HIV-related stigma and discrimination. Few studies have
measured the actual impact of disclosure on children’s clinical,
emotional and psychosocial outcomes. [8] Anecdotal evidence
from qualitative and quantitative studies suggests both positive and
negative effects of disclosure on disease progression, adherence to
ART, caregiver-child relationships, access to social support and
psychological health outcomes.
As children in HIV care systems mature through adolescence,
more data on disclosure of their HIV status in resource-limited
settings are needed. These data will help inform the design and
adoption of culturally-relevant guidelines which providers and
other health professionals can use to support caregivers and
children through this difficult process. Previously, we reported the
results of a pilot study on the prevalence of disclosure among 270
HIV-infected children at a single urban clinic in western Kenya
[9] under the umbrella of the Academic Model Providing Access
to Healthcare (AMPATH), one of the largest HIV care systems in
sub-Saharan Africa. This article describes the results of the parent
study that assessed the prevalence of disclosure and factors
associated with disclosure among a larger sample drawn from 4
urban and rural AMPATH clinics across western Kenya.
Methods
Study Design
We conducted a cross-sectional study using assessments of a
random sample of caregivers and their HIV-infected children ages
6–14 years receiving care at four AMPATH clinics in western
Kenya. Clinicians independently administered a 17-item ques-
tionnaire to HIV-infected children and a 15-item questionnaire to
their caregivers at routine clinic visits to assess disclosure status,
ART adherence, stigma and depression (see Figure 1 for full set of
caregiver and child questionnaire items on the Disclosure
Questionnaire). Children were asked to leave the examination
room when clinicians were administering the questionnaire to
caregivers to avoid accidental disclosure. All children were asked
general questions about reasons for receiving care and disclosure
status, but only children who self-reported knowing their HIV
status were asked questions about HIV-related stigma and
depression. Caregivers were asked to respond to HIV-related
stigma and depression as experienced by their children. Depres-
sion symptoms were evaluated using the PHQ-2 questions, [10]
but other questionnaire items were developed in this setting.
Demographic and clinical characteristics of child participants were
extracted from chart review. Age, weight, orphan status,
medications, and duration of enrollment in AMPATH were
calculated at study visit. The most recent CD4 count and CD4
percentage (CD4%) in a child’s medical chart was used. No
demographic or other data were collected for caregivers. The
study was approved by the Institutional Review Board at Indiana
University School of Medicine in Indianapolis, Indiana, USA and
by the Institutional Research and Ethics Committee at Moi
University School of Medicine in Eldoret, Kenya. Consent and
assent were waived for this study as the questionnaires were
administered during routine visits with clinicians and the
assessments were in line with AMPATH’s protocol to begin
routine collection of disclosure data. Both the Institutional Review
Board at Indiana University School of Medicine and the
Institutional Research and Ethics Committee at Moi University
School of Medicine approved the waiving of consent and assent for
this study. Data were collected from July 2011 to June 2012.
Setting
AMPATH is a partnership between Moi University School of
Medicine, Moi Teaching and Referral Hospital (MTRH) and a
consortium of North American academic medical centers led by
Indiana University. [11] As of January 2013, AMPATH provides
comprehensive HIV care, including free ART and psychosocial
and nutritional support, to over 55,000 HIV-infected adults and
15,000 pediatric patients in 56 clinics and satellite sites across
western Kenya. AMPATH’s protocol on disclosure of HIV status
to children recommends initiating disclosure for all children who
are 10 years and above but the decision to disclose is ultimately left
to the child’s caregiver. Caregivers are invited to private and group
disclosure counseling sessions and offered support at the clinic that
includes information about HIV, discussing worries, fears and
potential advantages of disclosure and making a disclosure plan.
Children over 14 years of age, those without caregivers and those
at risk of endangering themselves through poor adherence or
others through sexual activity are often identified for enhanced
disclosure counseling.
Study Participants
The study population was caregivers and their HIV-infected
children ages 6 to 14 years who were enrolled in care at 4
AMPATH clinics: MTRH, Kitale, Turbo, and, Webuye. These
clinics were selected because they are among AMPATH’s largest
pediatric sites and treat geographically and ethnically diverse
patient populations. A ‘‘caregiver’’ was defined as someone
responsible for the well-being of the child, who brought the child
to clinic, and who was knowledgeable about the child’s HIV care
behaviors (e.g., adherence to ART). HIV infection was defined as
having one positive HIV DNA PCR test or one positive HIV
ELISA antibody test. A patient randomization module within the
electronic health record system was used to select a random
sample of HIV-infected patients ages 6 to 14 years enrolled in care
at the 4 study clinics. Disclosure status was not recorded in the
electronic data and was not considered in the inclusion criteria.
The minimum age limit was based on a previous pilot study that
included a subset of this population [9] while the maximum age
limit was selected because children aged 15 years and above are
often treated in adult care settings where HIV disclosure is
assumed. No incentives were provided to study participants for
participation.
Outcomes
The outcome variable was children’s disclosure status, defined
as a binomial variable of ‘‘disclosed’’ versus ‘‘not disclosed.’’
Children were considered disclosed if the caregiver answered
‘‘yes’’ to any of the questions about the child knowing about their
HIV status (see Figure 1, Caregiver Items 1–4) or if the child
reported HIV as the reason he/she comes to clinic or takes
medications, the name of his/her illness or if he/she reported
being told their illness is HIV (see Figure 1, Child Items 1–3, 9).
Data Analysis
Descriptive statistics were calculated and the prevalence of
disclosure was described for child participants and within
subcategories by age. Univariate analyses with Pearson’s chi-
squared (x2) tests were used to investigate associations between a
child’s disclosure status and child-level demographic, clinical and
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psychosocial characteristics. Multivariate analyses were then
conducted using logistic regression with odds ratios (OR) and
95% confidence intervals (95%CI). As this was a largely
exploratory analysis, we included the entire set of variables in
the multivariate model whether they were significant in univariate
analyses or not. Binomial variables were calculated to describe
child-level adherence, stigma and depression based on child and
caregiver responses.
‘‘Non-adherence’’ was defined as any missed doses in the past
30 days by caregiver-report or child-report on the standard
AMPATH clinical encounter form or any indication of adherence
difficulties reported by caregivers (see Figure 1, Caregiver Items 7–
10) or children (see Figure 1, Child Items 4–8) on the Disclosure
Questionnaire. ‘‘Stigma’’ was defined as any indication of child-
experienced stigma from the caregiver (see Figure 1, Caregiver
Items 11–13) or the child (see Figure 1, Child Items 12–14) and
‘‘depression’’ was defined by any indication of child depression
symptoms as reported by the caregiver (see Figure 1, Caregiver
Items 14, 15) or the child (see Figure 1, Child Items 15, 16) using
the PHQ-2. All statistical analyses were performed using STATA
version 10.0 (StataCorp LP, College Station, Texas, USA).
Results
Characteristics of Child Participants
Among 792 children, mean age was 9.8 years (SD=2.6) and
51% were female (Table 1). Children had a mean weight-for-age
Z-score (WAZ) of 21.3 (SD=1.2). Almost half of the children
were orphans (48%) with orphan defined as having a deceased
biological mother, having a deceased biological father or having
both. The biological mother was the caregiver for a little over half
of the children (60%). Most children were on ART (79%), while
only 16 children (2%) were also taking anti-tuberculosis medica-
tion. Children had a mean duration of enrollment in an
AMPATH clinic of 48 months (SD=25.3) and mean CD4% of
28% (SD=0.16). Only 8% of children had indications of non-
adherence to ART on the standard clinical encounter form.
Prevalence of Disclosure
The overall prevalence of disclosure was 26%. The proportion
of children who knew their status was greater among older
children compared to young children. Disclosure by age is shown
in Table 1. While only 9% of 6- to 7-year olds knew their status,
33% of 10- to 11-year olds and 56% of 13- to 14-year olds
reported knowing their status (Figure 2). The prevalence of
disclosure also differed by clinic: disclosure prevalence was highest
at Webuye (40%) and lowest at MTRH (17%).
Association between Disclosure and Child Characteristics
In univariate analyses, older age (p,.01), being an orphan
(p = .04), having a lower CD4 count (p = .03), being on ART
(p= .01), ethnic group (p,.01) and treatment site (p,.01) were all
significantly associated with knowing one’s status (Table 1). While
disclosure status was not associated with adherence either reported
on the clinical encounter form or by caregivers, disclosure was
associated with child-reported adherence (p= .03) with disclosed
children reporting more non-adherence than non-disclosed
children (Table 2). Caregiver-reported child-experienced stigma
and child depression symptoms were both significantly associated
with disclosure; while only 2% caregivers of non-disclosed children
reported stigma and 4% reported depression symptoms, 10% of
caregivers of disclosed children reported stigma (p,.01) and 12%
reported depression symptoms (p,.01).
In multivariate analyses, variables significantly associated with
disclosure were a child’s older age (OR 1.5, 95%CI 1.3–1.6), being
on ART (OR 2.3, 95%CI 1.3–4.0), and caregiver-reported child
depression symptoms (OR 2.6, 95%CI 1.1–6.2) (Table 3).
Treatment site was also associated with disclosure at two clinics;
being treated at Webuye compared to MTRH was significantly
associated with disclosure (OR 3.4, 95%CI 1.7–6.8). Children with
a deceased father tended to be more likely to know their status
than non-orphans (OR 1.6, 95%CI 0.9–2.8), as did children with
caregivers who reported experiences of HIV stigma (OR 2.4,
95%CI 0.9–6.2), but neither test reached statistical significance.
Gender, primary caregiver, CD4%, duration enrolled in AM-
PATH, malnutrition and adherence were not associated with
disclosure in multivariate regression.
Child versus Caregiver-reported Variables
Child-reported versus caregiver-reported variables related to
disclosure status, adherence to ART, and experiences of stigma
and depression were analyzed to identify discrepancies. Caregivers
were more likely to report that the child knew their HIV status
(p,.01), had poor adherence (p,.01), and had experiences with
HIV-related stigma (p,.01) and depression symptoms (p,.01)
compared to children’s self-reports.
Discussion
As children with HIV survive into adolescence and adulthood at
unprecedented rates, disclosure of HIV status is an essential
component of pediatric HIV care and long-term disease manage-
ment. This study investigated the prevalence and correlates of
disclosure of HIV status to children in 4 clinics in western Kenya.
We found a minority of children aged 6–14 years knew their
status, consistent with findings from studies in Ghana, [12]
Uganda, [13] and a previous study in Nairobi, Kenya, which
found prevalence of disclosure to be 19% among 271 children with
a median age of 9 years. [14] We did, however, find higher rates of
disclosure in this expanded sample compared to rates of disclosure
in a pilot study that revealed only 11% of children (median age 9.3
years) knew their HIV status. The results of this study prompted a
program-wide reevaluation of AMPATH disclosure protocols and
retraining of clinic-level staff. We are also now in the process of
evaluating a 2–year disclosure intervention that includes further
training of disclosure staff, employment of dedicated disclosure
counselors and tailored disclosure curricula and materials.
Our study revealed a number of associations between disclosure
status and demographic and clinical characteristics. Older children
knew their status more frequently than younger children, likely as
a result of increasing maturity, independence and responsibility for
self-care that required knowledge of their status. For example, our
finding that those on ART were significantly more likely to know
their status may reflect disclosure following increased disease
management activities like taking ART. We did not find any
associations between disclosure status and clinical indicators like
CD4 count and WHO disease stage. A study among Thai
adolescents found that while disclosure was associated with CD4%
below 30% in multivariate analysis, disclosure status was not
associated with virologic outcomes. [15] In contrast, a study in
Romania found that children who did not know their HIV status
were at higher risk for disease progression, measured by CD4
count decline and death compared to disclosed children. [16]
Other clinic-level factors like retention in care may also be
associated with disclosure status and are important to understand,
however, we did not evaluate retention in care in this study.
Disclosure of HIV Status to Children in Kenya
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Table 1. Demographic and Clinical Characteristics of Child Participants by Disclosure Status.
Disclosed No (N=588) Disclosed Yes (N=204) P-Value{
Variable N % N %
Gender
Female 298 51% 107 52% 0.663
Male 290 49% 97 48%
On ART
Yes 450 24% 174 86% 0.006*
No 138 76% 29 14%
On Anti-TB
Yes 14 2% 2 1% 0.221
No 572 98% 201 99% 0.221
WHO Stage
1 135 23% 64 32% 0.079
2 142 24% 41 20%
3 271 46% 89 44%
4 39 7% 9 4%
Orphan Status
Both parents living 325 55% 91 45% 0.043*
Both parents dead 70 12% 35 17%
Mother dead 57 10% 23 11%
Father dead 79 13% 28 19%
Do not know 57 10% 17 8%
Caregiver
Mother 347 59% 104 51% 0.382
Father 56 9% 19 9%
Aunt/Uncle 69 125 28 14%
Grandparent 52 9% 19 9%
Sibling 18 3% 9 5%
Children’s Home 15 3% 8 4%
Other 31 5% 17 8%
Ethnic Group
Kalenjin 168 29% 36 17% 0.001*
Kikuyu 69 12% 18 9%
Luhya 265 45% 126 62%
Luo 47 8% 12 6%
Other 39 6% 12 6%
Clinic
MTRH 223 38% 47 23% ,0.001*
Kitale 123 21% 44 22%
Turbo 132 22% 40 19%
Webuye 110 19% 73 36%
Adherence on Clinic Encounter
(30-day recall)
Adherent 542 92% 185 91% 0.504
Non-adherent 46 8% 19 9%
Mean SD Mean SD
Age (years) 9.4 2.2 11.4 2.3 ,0.001*
Disclosure of HIV Status to Children in Kenya
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The relationship between adherence to ART and disclosure is
not well described and studies report mixed results.[17–19] There
are several reasons disclosure might be associated with non-
adherence. Disclosure is a traumatic event for many children and
can be accompanied by feelings of anger, hopelessness and
rebellion, which may lead to temporary or longer-term adherence
problems. The negative effects of HIV-related stigma, including
efforts to keep the diagnosis secret by hiding or not taking
medicines, may also impact adherence to therapy for disclosed
children more than non-disclosed children. Adherence issues may
be compounded by other adolescent-specific factors such as
increased incidence of depression [20] and generally poorer
medication adherence among this age group. [21] On the other
hand, there are also reasons to believe disclosure may lead to
improved adherence, including increased responsibility over
medication-taking and better access to social support. Pediatric
HIV providers often recommend disclosure of HIV status to
children as necessary to building trusting provider-patient and
family relationships and developing disease management skills that
facilitate adherence. [22] In the only longitudinal study to assess
adherence pre- and post-disclosure, Blasini et al reported that
approximately 58% of children and their caregivers reported that
adherence improved post-disclosure; however, adherence was
assessed by self- and proxy-report among a small sample of only 40
children and clinicians felt that adherence improved in only 25%
of cases. [23] Furthermore, since the study assessed disclosure after
an intensive, supportive disclosure intervention, its results may not
be representative of the majority of disclosure experiences.
Our finding that reports of adherence differed significantly
depending on whether adherence was caregiver-reported or child-
reported is indicative of the ongoing difficulties of clinic-level staff
in resource-limited settings to accurately assess adherence to ART.
A systematic review on adherence to ART found that adherence
assessment items are rarely validated, that proxy-reports (i.e.,
caregiver-reports) often overestimate adherence and that children
report more non-adherence than their caregivers do. [24] In our
study, children reported less non-adherence than their caregivers,
but these findings may be shaped by several cultural-specific
biases. In particular, children in this setting with strong cultural
traditions requiring children to obey authority figures (i.e.,
caregivers and clinicians) may be more vulnerable to social
desirability pressure to report higher adherence. [25] In addition,
despite clinical protocols recommending private interviewing of
children about adherence, children are seldom questioned in
private as was required for completion of the evaluations within
this study. Finally, many of the children involved in this study were
in the care of their grandparents and other extended family
members rather than their biological parents. These non-parent
caregivers may feel less pressure to report adherence.
Few studies investigate the psychosocial impact of disclosure in
resource-limited settings. While this study was not designed to
assess the impact by pre- and post-disclosure characteristics, we
found higher rates of experiences of HIV-related stigma and
depression symptoms among disclosed children, although only
depression symptoms were significantly associated with disclosure
in multivariate regression. This finding contradicts the findings of
studies from the US and Zambia that suggest non-disclosed
Figure 2. Prevalence of disclosure by age.
doi:10.1371/journal.pone.0086616.g002
Table 1. Cont.
Disclosed No (N=588) Disclosed Yes (N=204) P-Value{
Variable N % N %
Time enrolled at AMPATH clinic (months) 47.9 24.9 47.6 24.9 0.967
CD4 Count 793.5 453.4 712.3 386.3 0.035*
CD4% 0.29 0.18 0.27 0.10 0.582
{Univariate analyses using Pearson’s chi-squared tests.
*Significant at the p,0.05 level.
doi:10.1371/journal.pone.0086616.t001
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children have increased levels of psychological distress, including
anxiety and depression, internalizing behavioral problems and
poorer psychological adjustment compared to children that know
their status.[26–28] In one of the few longitudinal studies
measuring the psychosocial impact of disclosure, Butler et al
found no significant association between caregiver-reported
quality of life indicators pre- and post-disclosure among 395
perinatally HIV-infected children in the US Pediatric AIDS
Clinical Trials Group 219C. [29] Our findings highlight the need
to investigate the impact of disclosure on emotional and mental
health outcomes in settings like Kenya so that appropriate support
services can be provided.
Significant variations in the prevalence of disclosure among the
clinics included in this study deserve further attention. Our
analyses may not capture significant clinic-level factors, such as
clinic staff motivated or experienced in disclosure; cultural factors
such as varying populations of ethnic groups with differing
perspectives on disclosure; or other structural factors like urban
versus rural characteristics and transportation time and cost to
clinic. In our sample, the prevalence of disclosure was highest at
Webuye (39.9%), one of the rural satellite clinics, and was
significantly lower at MTRH (17.4%), the second largest referral
hospital in the country located in an urban center. Interestingly,
caregivers of children attending Webuye clinic also reported
significantly higher medication adherence (63.4%) than caregivers
of children at MTRH (28.8%). We are aware of at least one nurse
counselor at the Webuye clinic who expressed high interest in
disclosure and its impact on care, which may contribute to the
clinic’s higher rates of disclosure. While AMPATH clinics
routinely offer counseling (including disclosure counseling) and
support group services to children and their caregivers, we did not
investigate differences in clinic-level services or their utilization by
study group participants. Identifying clinic-level factors that
promote or impede disclosure may help shape best practices for
pediatric HIV care.
Many factors influence how and when caregivers decide to
disclose to a child. This study did not assess caregiver perspectives
on disclosure; however, previous qualitative work in this setting
found that caregivers of HIV-infected children weighed potential
risks and benefits as they made their decisions about when to
disclose. [30] Perceived risks in this setting included the child being
too young to understand, negative emotional consequences for the
child and the subsequent disclosure of the child’s status to others,
resulting in stigma and discrimination. At least one study found
that children who disclosed their status to friends over the study
period showed greater improvements in CD4 cell counts than
children who had not disclosed, which may suggest better health
outcomes after engaging social support. [31] On the other hand,
caregivers believed that disclosure might lead to positive changes,
including the child asking fewer questions, improved adherence to
medications, and better access to social support. These findings are
consistent with perspectives of caregivers in other resource-rich
and resource-limited settings, who identify similar risks and
benefits of disclosure. [7] While not significant, we found some
indication that disclosure status varies by ethnic group in our
setting in western Kenya. More qualitative data are needed to
further explore how cultural beliefs may impact decisions about
how and when to disclose HIV status to children in this setting.
Table 2. Indicators of Adherence, Stigma and Depression by Caregiver- and Child-Report.
Disclosed No (N=588) Disclosed Yes (N=204) P-Value{
Variable N % N %
Caregiver-Reported Variables:
Combined Adherence
Adherent 280 48% 92 45% 0.534
Non-adherent 308 52% 112 55%
Combined Stigma
No reported stigma 575 98% 184 90% ,0.001*
Reported stigma 13 2% 20 10%
Combined Depression
No reported depression 566 96% 180 88% ,0.001*
Reported depression 22 4% 24 12%
Child-Reported Variables:
Combined Adherence
Adherent 488 83% 155 76% 0.027*
Non-adherent 100 17% 49 24%
Combined Stigma**
No reported stigma – – 189 93% –
Reported stigma – – 15 7% –
Combined Depression** – – –
No reported depression – – 195 96% –
Reported depression – – 9 4% –
{Univariate analyses using Pearson’s chi-squared tests.
*Significant at the p,0.05 level.
**Only disclosed children were asked questions about stigma and depression.
doi:10.1371/journal.pone.0086616.t002
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This study had a number of limitations for consideration.
One limitation was that we did not assess the prevalence of
partial disclosure, where a child has incomplete information
about HIV, which may be part of an age-appropriate disclosure
process. [32] We counted any knowledge of HIV as a reason
for treatment as disclosure. In other cases, caregivers or
healthcare providers may give inaccurate information regarding
the child’s diagnosis, such as attributing the illness, medication
or clinic responsibilities to a different, often less-stigmatized
condition like tuberculosis. Investigating how partial disclosure
and misinformation are used by caregivers and healthcare
providers and the impact on full disclosure, clinical outcomes,
and psychosocial outcomes are important to understand. We
also did not consider whether time since diagnosis or duration
on ART were associated with disclosure of HIV status. In this
setting, the vast majority of children are perinatally infected and
thus diagnosed at birth or shortly thereafter but age at ART
initiation varies from child to child. Time since diagnosis and
duration on ART may be important factors associated with
disclosure [33] and should be investigated in this setting.
Another potential limitation of this study was the validity of the
proxy- and self-reports for obtaining information on disclosure
status, adherence, and experiences of stigma and depression.
Validated measures for assessing disclosure status do not exist,
so we attempted to use a variety of questionnaire items,
evaluating potential aspects of disclosure such as whether the
child knew their disease, the name of their disease, why they
took medicines, or why they attended clinic. We used the PHQ-
2 depression screening questions because they have reasonable
validity and reliability among HIV-infected adults in western
Kenya [34] and adolescents in the US [35] but there are no
such studies on depression screening among children and
adolescents in this setting. No validated measures for HIV-
related stigma currently exist for this population. [36] Data
related to disclosure were collected in the context of a routine
HIV clinic visit, which limits the data points available. It is also
possible that the caregivers or children may have been hesitant
to discuss disclosure status, adherence, stigma, or depression
Table 3. Factors Associated with Disclosure Status in Multivariate Regression Model.
Variable Odds Ratio 95% Confidence Interval
Female vs. Male 0.81 0.55–1.20
Age 1.49 1.35–1.63*
On ART (Yes vs. No) 2.26 1.29–3.97*
On Anti-TBs (Yes vs. No) 0.15 0.01–2.50
Time enrolled at AMPATH clinic 1.00 0.99–1.01
CD4% 0.54 0.14–2.05
Orphan Status
Total orphan vs. Non-orphan 1.19 0.49–2.90
Mother dead vs. Non-orphan 0.87 0.39–1.97
Father dead vs. Non-orphan 1.62 0.92–2.85
Parent status unknown vs. Non-orphan 1.35 0.53–3.48
Malnutrition
Mild malnutrition vs. Normal 1.06 0.66–1.71
Moderate malnutrition vs. Normal 1.07 0.61–1.89
Severe malnutrition vs. Normal 0.75 0.26–2.16
Disease Stage
WHO Stage II vs. WHO Stage I 0.62 0.35–1.09
WHO Stage III vs. WHO Stage I 0.72 0.43–1.21
WHO Stage IV vs. WHO Stage I 0.41 0.15–1.08
Ethnic Group
Kikuyu vs. Kalenjin 1.42 0.66–3.12
Luhya vs. Kalenjin 1.66 0.95–2.90
Luo vs. Kalenjin 1.74 0.72–4.20
Clinic
Webuye vs. MTRH 3.44 1.75–6.76*
Kitale vs. MTRH 1.94 0.96–3.92
Turbo vs. MTRH 1.50 0.76–2.95
Caregiver-reported variables
Non-adherent vs. Adherent 1.31 0.86–1.98
Reported stigma vs. No reported stigma 2.39 0.93–6.18
Reported depression vs. No reported depression 2.63 1.12–6.20*
*Significant in multivariate regression (95%CI does not include 1.00).
doi:10.1371/journal.pone.0086616.t003
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symptoms with their regular clinician. Nonetheless, our intent
was to make these discussions a routine part of the clinical
encounter between clinician and family or patient, and asking
these questions as part of the clinical visit modeled that patient-
physician interaction. Finally, the cross-sectional design of this
study did not allow us to measure disclosure rates of HIV status
to children, causal pathways of disclosure or the potential
impact of disclosure on clinical and psychosocial outcomes.
Longitudinal cohort studies on disclosure of HIV status in this
setting are urgently needed to answer these important questions
as more HIV-infected children and adolescents make the
difficult transition to adulthood.
Conclusions
This sample from a large, pediatric HIV care program in sub-
Saharan Africa suggests a low prevalence of disclosure of HIV
status to children, while highlighting how disclosure may be
related to key outcomes such as medication adherence, experi-
ences of stigma, and symptoms of depression. More data are
needed to better understand the impact of disclosure and to inform
disclosure support interventions as children and their families go
through this challenging process.
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